A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Joshua F. Zeidner; Tara L. Lin; Carlos E. Vigil; Gil Fine; M. Yair Levy; Aziz Nazha; Jordi Esteve; Daniel J. Lee; Karen Yee; Andrew Dalovisio; Eunice S. Wang; Juan M. Bergua Burgues; Jeffrey Schriber; Mark R. Litzow; Olga Frankfurt; Teresa Bernal Del Castillo; Vijaya Raj Bhatt; Bhavana Bhatnagar; Priyanka Mehta; Richard Dillon; Maria Vidriales Vicente; Stephen Anthony; David Bearss; Pau Montesinos; B. Douglas Smith

doi:10.1038/s41408-021-00568-3

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen Yee, Andrew Dalovisio, Eunice S. Wang, Juan M. Bergua Burgues, Jeffrey Schriber, Mark R. Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard DillonMaria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B. Douglas Smith

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Article number	175
Journal	Blood Cancer Journal
Volume	11
Issue number	10
DOIs	https://doi.org/10.1038/s41408-021-00568-3
State	Published - Oct 2021

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-021-00568-3

Cite this

Zeidner, J. F., Lin, T. L., Vigil, C. E., Fine, G., Yair Levy, M., Nazha, A., Esteve, J., Lee, D. J., Yee, K., Dalovisio, A., Wang, E. S., Bergua Burgues, J. M., Schriber, J., Litzow, M. R., Frankfurt, O., Castillo, T. B. D., Bhatt, V. R., Bhatnagar, B., Mehta, P., ... Douglas Smith, B. (2021). A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood Cancer Journal, 11(10), Article 175. https://doi.org/10.1038/s41408-021-00568-3

Zeidner, JF, Lin, TL, Vigil, CE, Fine, G, Yair Levy, M, Nazha, A, Esteve, J, Lee, DJ, Yee, K, Dalovisio, A, Wang, ES, Bergua Burgues, JM, Schriber, J, Litzow, MR, Frankfurt, O, Castillo, TBD, Bhatt, VR, Bhatnagar, B, Mehta, P, Dillon, R, Vicente, MV, Anthony, S, Bearss, D, Montesinos, P & Douglas Smith, B 2021, 'A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia', Blood Cancer Journal, vol. 11, no. 10, 175. https://doi.org/10.1038/s41408-021-00568-3

@article{124ad71886554d1c906da87e23124c8e,

title = "A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia",

author = "Zeidner, {Joshua F.} and Lin, {Tara L.} and Vigil, {Carlos E.} and Gil Fine and {Yair Levy}, M. and Aziz Nazha and Jordi Esteve and Lee, {Daniel J.} and Karen Yee and Andrew Dalovisio and Wang, {Eunice S.} and {Bergua Burgues}, {Juan M.} and Jeffrey Schriber and Litzow, {Mark R.} and Olga Frankfurt and Castillo, {Teresa Bernal Del} and Bhatt, {Vijaya Raj} and Bhavana Bhatnagar and Priyanka Mehta and Richard Dillon and Vicente, {Maria Vidriales} and Stephen Anthony and David Bearss and Pau Montesinos and {Douglas Smith}, B.",

note = "Funding Information: J.F.Z. has served as a consultant for AbbVie and Takeda; received honoraria from advisory boards from Agios/Servier, Bristol Myers Squibb/Celgene, Genentech, Gilead, Shattuck Labs, and Takeda and has received research funding from Arog, Astex, Gilead/Forty Seven, Merck, Sumitomo Dainippon Pharma/Tolero, Takeda. G.F., S.A., and D.B. were employed by Sumitomo Dainippon Pharma. D.J.L. received consulting fees from Celgene and research funding (institutional) from AbbVie, Bayer, Genentech, Gilead/Forty Seven, Novartis, and Tolero. At the time of publication, D.J.L. will be employed by Cellectis. K.Y. consulted for and/or received honorarium from Novartis, F. Hoffmann La Roche, Shattuck Labs, Takeda, Pfizer, TaiHo, Bristol-Myers Squib/Celgene, Paladin, Astex, and Otsuka and has received research funding from Astex, Novartis, Forma Therapeutics, Jazz, Onconova, F. Hoffmann La Roche, Genentech, and Tolero. E.S.W. has received honoraria from advisory boards from AbbVie, Astellas, BMS/Celgene, Genentech, GlaxoSmithKline, Jazz, Kite Pharmaceuticals, Kura Oncology, Novartis, Pfizer, Stemline, and Takeda; consultancy from Mana Therapeutics; speaker role for Stemline, Kura, Pfizer, and Dava Oncology; and has served on data monitoring committees with AbbVie and Rafael Pharmaceuticals. M.R.L. has served on advisory boards from Omeros and Jazz; has served on Data Monitoring Committee with Biosight; and receives research funding from AbbVie, Astellas, Amgen, Actinium, and Pluristem. P.M. has received advisory board honoraria from Pfizer, Jazz Pharmaceuticals, AbbVie, Celgene, Daichii Sankyo, and Takeda and educational grant from Jazz Pharmaceuticals, Daichii Sankyo, Novartis, and Celgene. R.D. has received honoraria from advisory boards from AbbVie, Jazz, Menarini, Novartis, and Pfizer; consultancy from AbbVie, Astellas, Jazz, Novartis, and Pfizer; and research funding from AbbVie and Amgen. V.R.B. is receiving consulting fees from Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Partnership for health analytic research, LLC (which, in turn, receives funds from Jazz Pharmaceuticals), and AbbVie, research funding (institutional) from AbbVie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program; drug support (institutional) from Oncoceutics for a trial; and educational grant (institutional) from Pfizer and Novartis. B.D.S. has served as a consultant for Bristol Myers Squibb/Celgene, Jubilant, Novartis, and Pfizer and has served on DSMB for Bristol Myers Squibb/Celgene and Cellularity. All other authors declare no competing interests or disclosures. Funding Information: This study was supported by Tolero Pharmaceuticals, acquired by Sumitomo Dainippon Pharma.",

year = "2021",

month = oct,

doi = "10.1038/s41408-021-00568-3",

language = "English (US)",

volume = "11",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

AU - Zeidner, Joshua F.

AU - Lin, Tara L.

AU - Vigil, Carlos E.

AU - Fine, Gil

AU - Yair Levy, M.

AU - Nazha, Aziz

AU - Esteve, Jordi

AU - Lee, Daniel J.

AU - Yee, Karen

AU - Dalovisio, Andrew

AU - Wang, Eunice S.

AU - Bergua Burgues, Juan M.

AU - Schriber, Jeffrey

AU - Litzow, Mark R.

AU - Frankfurt, Olga

AU - Castillo, Teresa Bernal Del

AU - Bhatt, Vijaya Raj

AU - Bhatnagar, Bhavana

AU - Mehta, Priyanka

AU - Dillon, Richard

AU - Vicente, Maria Vidriales

AU - Anthony, Stephen

AU - Bearss, David

AU - Montesinos, Pau

AU - Douglas Smith, B.

N1 - Funding Information: J.F.Z. has served as a consultant for AbbVie and Takeda; received honoraria from advisory boards from Agios/Servier, Bristol Myers Squibb/Celgene, Genentech, Gilead, Shattuck Labs, and Takeda and has received research funding from Arog, Astex, Gilead/Forty Seven, Merck, Sumitomo Dainippon Pharma/Tolero, Takeda. G.F., S.A., and D.B. were employed by Sumitomo Dainippon Pharma. D.J.L. received consulting fees from Celgene and research funding (institutional) from AbbVie, Bayer, Genentech, Gilead/Forty Seven, Novartis, and Tolero. At the time of publication, D.J.L. will be employed by Cellectis. K.Y. consulted for and/or received honorarium from Novartis, F. Hoffmann La Roche, Shattuck Labs, Takeda, Pfizer, TaiHo, Bristol-Myers Squib/Celgene, Paladin, Astex, and Otsuka and has received research funding from Astex, Novartis, Forma Therapeutics, Jazz, Onconova, F. Hoffmann La Roche, Genentech, and Tolero. E.S.W. has received honoraria from advisory boards from AbbVie, Astellas, BMS/Celgene, Genentech, GlaxoSmithKline, Jazz, Kite Pharmaceuticals, Kura Oncology, Novartis, Pfizer, Stemline, and Takeda; consultancy from Mana Therapeutics; speaker role for Stemline, Kura, Pfizer, and Dava Oncology; and has served on data monitoring committees with AbbVie and Rafael Pharmaceuticals. M.R.L. has served on advisory boards from Omeros and Jazz; has served on Data Monitoring Committee with Biosight; and receives research funding from AbbVie, Astellas, Amgen, Actinium, and Pluristem. P.M. has received advisory board honoraria from Pfizer, Jazz Pharmaceuticals, AbbVie, Celgene, Daichii Sankyo, and Takeda and educational grant from Jazz Pharmaceuticals, Daichii Sankyo, Novartis, and Celgene. R.D. has received honoraria from advisory boards from AbbVie, Jazz, Menarini, Novartis, and Pfizer; consultancy from AbbVie, Astellas, Jazz, Novartis, and Pfizer; and research funding from AbbVie and Amgen. V.R.B. is receiving consulting fees from Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Partnership for health analytic research, LLC (which, in turn, receives funds from Jazz Pharmaceuticals), and AbbVie, research funding (institutional) from AbbVie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program; drug support (institutional) from Oncoceutics for a trial; and educational grant (institutional) from Pfizer and Novartis. B.D.S. has served as a consultant for Bristol Myers Squibb/Celgene, Jubilant, Novartis, and Pfizer and has served on DSMB for Bristol Myers Squibb/Celgene and Cellularity. All other authors declare no competing interests or disclosures. Funding Information: This study was supported by Tolero Pharmaceuticals, acquired by Sumitomo Dainippon Pharma.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85118437389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118437389&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00568-3

DO - 10.1038/s41408-021-00568-3

M3 - Letter

C2 - 34718324

AN - SCOPUS:85118437389

SN - 2044-5385

VL - 11

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 10

M1 - 175

ER -

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this